http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2647932-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_caec7099b724bb45d2518787825aab94 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 |
| filingDate | 2006-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c8b5fe4832c6c5def5c79ac99c913a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b893e8ef34926ef2da9d4c10f1e60290 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecc6e8fe906746f7ebbb98c4ce5b7ca3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c11afefa1e3cdf11c7a600b7d5c90f1c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71ecb7b40e6705c3e8796d065a09d23e |
| publicationDate | 2011-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2647932-C |
| titleOfInvention | Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound |
| abstract | The present invention relates to an agent for preventing and treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) associated with BPH and a relaxant for relaxing urethral smooth muscle or prostatic smooth muscle comprising a pyrazolopyrimidinone compound as an effective ingredient. The agent in accordance with the present invention can provide nitric oxides by inhibiting the activity of PDE-5 that decomposes c-GMP, and the provided nitric oxides relax the urethral smooth muscle or the prostatic smooth muscle to lower the intraurethral pressure (IUP), thus treating BPH and LUTS associated with BPH. Furthermore, the time required for reaching a maximum blood concentration is shorter and the half-life is longer than the other PDE-5 inhibitors, thus reducing the frequency of administration. Moreover, the agent of the invention causing few side effects can be efficiently used as a safe drug. |
| priorityDate | 2006-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 152.